Immunovant (IMVT)
(Real Time Quote from BATS)
$29.43 USD
-1.49 (-4.82%)
Updated Jul 17, 2024 01:52 PM ET
4-Sell of 5 4
D Value D Growth C Momentum F VGM
Brokerage Reports
Immunovant, Inc. [IMVT]
Reports for Purchase
Showing records 1 - 20 ( 105 total )
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Accelerating IMVT-1402 Across Multiple Indications, Though Near-Term Readouts Delayed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Long Overlooked, Graves? Disease Goes In Vogue With New Approaches
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Pedal to the Metal for Immunovant as It Looks to Keep Pace with Competitors in FcRn Space; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Initial Data in Grave''s Disease Gives Immunovant an Indication to Itself; Target to $51
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department